文献速递瓣膜外科主动脉外科

主动脉同种移植物治疗自体与人工瓣膜及根部心内膜炎:EURECAH注册研究结果

Aortic homografts for native and prosthetic aortic valve and root endocarditis: Results from the EUropean REgistry of Cryopreserved Aortic Homografts EURECAH.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-05-25

EURECAH多中心注册回顾分析2000至2025年544例因复杂主动脉自体或人工瓣膜心内膜炎行主动脉同种移植物瓣膜/根部替换的患者,中位年龄65岁,78%为男性。围术期死亡15%,总生存率30天87.9%、1年78.5%、5年67.1%、10年52.8%,中位生存10.2年;14%再干预,结构性瓣膜功能障碍6%、感染性心内膜炎复发3%。结论认为尽管病情复杂,该策略安全且早晚期生存满意,远期耐久性好、复发心内膜炎率低。

要点

  • 主动脉同种移植物用于复杂主动脉瓣/根部心内膜炎安全,早晚期生存满意。
  • 围术期死亡15%,10年生存率52.8%,中位生存10.2年。
  • 再干预率14%,结构性瓣膜功能障碍6%,复发感染性心内膜炎3%。

核心结论

  • EURECAH注册研究显示,主动脉同种移植物治疗自体与人工主动脉瓣及根部心内膜炎安全,早晚期生存满意,远期耐久性好且复发心内膜炎率低。

研究设计与样本

  • 患者中位年龄65[54-73]岁,78%为男性;自体瓣膜心内膜炎188例(35%),人工瓣膜心内膜炎356例(65%)。

主要发现

  • 合并环形脓肿369例(68%)、二尖瓣-主动脉瓣连接中断187例(34%)、二尖瓣心内膜炎84例(15%)、右侧心内膜炎24例(4%)。
  • 植入方式为全根部85%、自由hand冠状下11%、包埋技术4%;中位体外循环时间192[150-239]分钟,主动脉阻断时间147[115-182]分钟。
  • 随访期间死亡247例(45%),其中围术期85例(15%)、早期32例(6%)、晚期130例(24%);中位生存时间10.2[1.9-19.8]年。
  • 总生存率30天87.9%、1年78.5%、5年67.1%、10年52.8%。
  • 再干预77例(14%),原因包括结构性瓣膜功能障碍(6%)、感染性心内膜炎(3%)、非结构性瓣膜功能障碍(1%)、二尖瓣反流(2%)、冠心病(1%)、心脏移植(1%)、主动脉瘤(1%)。

临床怎么用

  • 对于合并环形脓肿、二尖瓣-主动脉瓣连接中断等复杂情况的主动脉自体或人工瓣膜心内膜炎,可考虑使用主动脉同种移植物行瓣膜/根部替换。
  • 需告知患者围术期死亡风险约15%、10年生存率约52.8%,以及再干预率14%、结构性瓣膜功能障碍6%、复发感染性心内膜炎3%的远期风险。

局限性

  • 为回顾性注册研究,非随机对照设计。
  • 仅纳入5个欧洲心脏中心,存在中心选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the early and late results of patients treated with an aortic homograft for complex aortic native and prosthetic valve endocarditis. METHODS: Clinical data of patients undergoing aortic valve/root replacement with an aortic homograft for infective endocarditis from 2000 to 2025 in 5 European cardiac centers were collected in the EUropean REgistry of Cryopreserved Aortic Homografts (EURECAH) and retrospectively analyzed. Follow-up data were collected until December 2025. RESULTS: In total, 544 patients, 78% of whom were male, with a median age of 65 [54-73] years, have been enrolled in the EURECAH, including 188 (35%) with native and 356 (65%) with prosthetic valve endocarditis complicated by 369 (68%) annular abscess, 187 (34%) mitroaortic discontinuity, 84 (15%) mitral valve, and 24 (4%) right-sided endocarditis. Aortic homografts were implanted with full root (85%), freehand subcoronary (11%), and the inclusion technique (4%). Median cardiopulmonary bypass time was 192 [150-239] minutes and aortic crossclamping time was 147 [115-182] minutes. In total, 247 (45%) patients died during follow-up, including 85 (15%) periprocedural, 32 (6%) early and 130 (24%) late deaths. Median survival time was 10.2 [1.9-19.8] years. Overall survival rates were 87.9% at 30 days, 78.5% at 1 year, 67.1% at 5 years, and 52.8% at 10 years. In total, 77 (14%) patients underwent reintervention for structural valve dysfunction (6%), infective endocarditis (3%), nonstructural valve dysfunction (1%), mitral valve regurgitation (2%), coronary artery disease (1%), heart transplantation (1%), and aortic aneurysm (1%). CONCLUSIONS: The results of the EURECAH registry show that the use of an aortic homograft for native and prosthetic aortic valve and root endocarditis is safe and provides satisfactory early and late survival despite the complexity of the condition, with good long-term durability and low rates of recurrent endocarditis.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Galeone A, Mastrobuoni S, Vobornik M, et al. Aortic homografts for native and prosthetic aortic valve and root endocarditis: Results from the EUropean REgistry of Cryopreserved Aortic Homografts EURECAH. J Thorac Cardiovasc Surg. 2026. PMID: 42190794. doi:10.1016/j.jtcvs.2026.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。